16:04:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.

Kalender

2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-06-06 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-05-10 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2020-11-05 12:21:05
Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS
to Mel-Mont Medical, Inc. The gross proceeds from the transaction is estimated
to NOK 7.7 million and will have an effect from 30 September 2020. Per 30
September 2020 PreTect had operating revenues of NOK 2.6 million and an EBITDA
of NOK -1.8 million. The transaction will result in a financial gain of
approximately NOK 4.5 million which will be booked in the fourth quarter of
2020.

Gentian Diagnostics acquired PreTect AS in 2016 and has supported the
development of clinical documentation pertaining to the relevance of PreTect's
HPV assays in the field of cervical cancer diagnostics- and prevention. Gentian
is proud to have contributed to a large trial, in close collaboration with the
University Hospital of North Norway in Tromsø, that has resulted in a unique
data base with samples from more than 100,000 women. A publication based on
these data has confirmed the advantages of using PreTect's mRNA technology as an
additional quality assurance to cytology in young women.

Despite these encouraging results Gentian Diagnostics has not been in a position
to expand the sales of PreTect HPV assays to a satisfactory level. Therefore,
following an internal review, Gentian has concluded that the future success of
PreTect will be best served if the Company is under the direct ownership of a
dedicated player in the market for HPV testing.

Commenting on the divestiture, Gentian Diagnostics CEO, Hilja Ibert says: "We
believe that with Mel-Mont Medical's existing business activity with
self-sampling of HPV testing the combination with PreTect makes perfect sense.
HPV testing is a highly specialised market which we believe will be better
served by a focused player. We would like to thank PreTect's highly motivated
and professional team and all our collaborators for their contributions over
these past four years."


For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525